EE200300475A - Tyrosine kinase inhibitors, pharmaceutical compositions containing them, and said compounds for use in the treatment of diseases - Google Patents
Tyrosine kinase inhibitors, pharmaceutical compositions containing them, and said compounds for use in the treatment of diseasesInfo
- Publication number
- EE200300475A EE200300475A EEP200300475A EEP200300475A EE200300475A EE 200300475 A EE200300475 A EE 200300475A EE P200300475 A EEP200300475 A EE P200300475A EE P200300475 A EEP200300475 A EE P200300475A EE 200300475 A EE200300475 A EE 200300475A
- Authority
- EE
- Estonia
- Prior art keywords
- diseases
- compounds
- treatment
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27932701P | 2001-03-28 | 2001-03-28 | |
| PCT/US2002/009402 WO2002079192A1 (en) | 2001-03-28 | 2002-03-26 | Novel tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200300475A true EE200300475A (en) | 2004-02-16 |
Family
ID=23068491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300475A EE200300475A (en) | 2001-03-28 | 2002-03-26 | Tyrosine kinase inhibitors, pharmaceutical compositions containing them, and said compounds for use in the treatment of diseases |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1381598A4 (en) |
| JP (1) | JP2004534010A (en) |
| KR (1) | KR20030083016A (en) |
| CN (1) | CN1514833A (en) |
| AR (1) | AR035804A1 (en) |
| BG (1) | BG108206A (en) |
| BR (1) | BR0208373A (en) |
| CA (1) | CA2442428A1 (en) |
| CZ (1) | CZ20032615A3 (en) |
| EE (1) | EE200300475A (en) |
| GE (1) | GEP20053660B (en) |
| HR (1) | HRP20030844A2 (en) |
| HU (1) | HUP0400323A2 (en) |
| IL (1) | IL158041A0 (en) |
| IS (1) | IS6968A (en) |
| MX (1) | MXPA03008690A (en) |
| NO (1) | NO20034308L (en) |
| PE (1) | PE20021015A1 (en) |
| PL (1) | PL373300A1 (en) |
| RU (1) | RU2003131693A (en) |
| SK (1) | SK12002003A3 (en) |
| UY (1) | UY27234A1 (en) |
| WO (1) | WO2002079192A1 (en) |
| YU (1) | YU84603A (en) |
| ZA (1) | ZA200307466B (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| WO2003073841A2 (en) | 2002-03-01 | 2003-09-12 | Bristol-Myers Squibb Company | Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors |
| CA2488635C (en) * | 2002-06-12 | 2012-10-23 | Abbott Laboratories | Antagonists of melanin concentrating hormone receptor |
| US7361691B2 (en) * | 2002-12-02 | 2008-04-22 | Arqule, Inc. | Method of treating cancers using β-lapachone or analogs or derivatives thereof |
| EP1581539A4 (en) * | 2003-01-03 | 2007-09-19 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
| US7329678B2 (en) * | 2003-01-28 | 2008-02-12 | Smithkline Beecham Corporation | Chemical compounds |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| AU2004268621C1 (en) * | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
| US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| DE102004010207A1 (en) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer |
| EP2308879A1 (en) | 2004-04-02 | 2011-04-13 | OSI Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| EP1778669A2 (en) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| RU2423351C2 (en) * | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Pyrid-2-ones applicable as protein kinase inhibitors of tec family for treating inflammatory, proliferative and immunologically mediated diseases |
| US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| WO2006130657A2 (en) | 2005-05-31 | 2006-12-07 | Bristol-Myers Squibb Company | Stereoselective reduction process for the preparation of pyrrolotriazine compounds |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| WO2007019416A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1919891B1 (en) | 2005-08-29 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| CA2620352A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| DE602006020293D1 (en) * | 2005-08-29 | 2011-04-07 | Vertex Pharma | 3,5-DISUBSTITUTED PYRID-2-ONE, WHICH ARE USES AS INHIBITORS OF THE TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES |
| WO2007026720A1 (en) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | Ring-fused pyrazole derivative |
| US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
| WO2007145203A1 (en) * | 2006-06-13 | 2007-12-21 | Daiichi Fine Chemical Co., Ltd. | Optically active 2-amino-1-(4-fluorophenyl)ethanol |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| WO2008022747A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
| WO2008025526A1 (en) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Indole derivatives, their manufacture and use as pharmaceutical agents |
| EP2559771A3 (en) | 2007-05-17 | 2013-06-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| EP2170859A1 (en) * | 2007-06-25 | 2010-04-07 | F. Hoffmann-Roche AG | Benzimidazole amido derivatives as kinase inhibitors |
| EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
| US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
| AU2009207478B2 (en) | 2008-01-22 | 2013-11-21 | Vernalis (R & D) Ltd | Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| WO2009143051A1 (en) | 2008-05-19 | 2009-11-26 | Osi Pharmaceuticals, Inc. | Substituted imidazopyr-and imidazotri-azines |
| US8343997B2 (en) | 2008-12-19 | 2013-01-01 | Sirtris Pharmaceuticals, Inc. | Thiazolopyridine sirtuin modulating compounds |
| DE102010001064A1 (en) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use |
| JP2012524119A (en) | 2009-04-20 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Preparation of C-pyrazine-methylamine |
| US8536180B2 (en) * | 2009-05-27 | 2013-09-17 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
| WO2011053779A2 (en) | 2009-10-30 | 2011-05-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
| US20130196990A1 (en) * | 2010-10-06 | 2013-08-01 | Junya Qu | Benzimidazole Derivatives As PI3 Kinase Inhibitors |
| US8772304B2 (en) * | 2010-11-01 | 2014-07-08 | Boehringer Ingelheim International Gmbh | Benzimidazole inhibitors of leukotriene production |
| WO2013056069A1 (en) | 2011-10-13 | 2013-04-18 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
| SI3010503T1 (en) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novel bicyclic bromodomain inhibitors |
| EP3010918B1 (en) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| JP6542212B2 (en) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | Novel quinazolinones as bromodomain inhibitors |
| CN103936719A (en) * | 2014-05-14 | 2014-07-23 | 中国药科大学 | Preparation method and application of benzimidazoles derivatives |
| CN108064274A (en) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | For cultivating the culture medium of multipotential stem cell |
| CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
| EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| CA2982664A1 (en) * | 2015-04-16 | 2016-10-20 | Merck Patent Gmbh | 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives |
| EP3914698B1 (en) | 2019-01-23 | 2024-12-11 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
| CN117069696B (en) * | 2023-08-17 | 2024-04-26 | 中国药科大学 | A dual-target small molecule inhibitor and its preparation method and application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DE50010931D1 (en) * | 1999-06-23 | 2005-09-15 | Aventis Pharma Gmbh | SUBSTITUTED BENZIMIDAZOLE |
| US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
-
2002
- 2002-03-26 BR BR0208373-6A patent/BR0208373A/en not_active IP Right Cessation
- 2002-03-26 WO PCT/US2002/009402 patent/WO2002079192A1/en not_active Ceased
- 2002-03-26 EE EEP200300475A patent/EE200300475A/en unknown
- 2002-03-26 CA CA002442428A patent/CA2442428A1/en not_active Abandoned
- 2002-03-26 EP EP02723631A patent/EP1381598A4/en not_active Withdrawn
- 2002-03-26 IL IL15804102A patent/IL158041A0/en unknown
- 2002-03-26 GE GE5363A patent/GEP20053660B/en unknown
- 2002-03-26 MX MXPA03008690A patent/MXPA03008690A/en unknown
- 2002-03-26 PL PL02373300A patent/PL373300A1/en not_active Application Discontinuation
- 2002-03-26 RU RU2003131693/04A patent/RU2003131693A/en not_active Application Discontinuation
- 2002-03-26 HR HR20030844A patent/HRP20030844A2/en not_active Application Discontinuation
- 2002-03-26 SK SK12002003A patent/SK12002003A3/en not_active Application Discontinuation
- 2002-03-26 CN CNA028105168A patent/CN1514833A/en active Pending
- 2002-03-26 YU YU84603A patent/YU84603A/en unknown
- 2002-03-26 JP JP2002577817A patent/JP2004534010A/en not_active Withdrawn
- 2002-03-26 HU HU0400323A patent/HUP0400323A2/en unknown
- 2002-03-26 KR KR10-2003-7012594A patent/KR20030083016A/en not_active Withdrawn
- 2002-03-26 CZ CZ20032615A patent/CZ20032615A3/en unknown
- 2002-03-27 PE PE2002000244A patent/PE20021015A1/en not_active Application Discontinuation
- 2002-03-27 UY UY27234A patent/UY27234A1/en not_active Application Discontinuation
- 2002-03-27 AR ARP020101167A patent/AR035804A1/en not_active Application Discontinuation
-
2003
- 2003-09-25 ZA ZA200307466A patent/ZA200307466B/en unknown
- 2003-09-26 NO NO20034308A patent/NO20034308L/en not_active Application Discontinuation
- 2003-09-26 BG BG108206A patent/BG108206A/en unknown
- 2003-09-26 IS IS6968A patent/IS6968A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03008690A (en) | 2003-12-12 |
| IL158041A0 (en) | 2004-03-28 |
| EP1381598A1 (en) | 2004-01-21 |
| PL373300A1 (en) | 2005-08-22 |
| BR0208373A (en) | 2005-02-22 |
| PE20021015A1 (en) | 2002-11-10 |
| CN1514833A (en) | 2004-07-21 |
| IS6968A (en) | 2003-09-26 |
| CA2442428A1 (en) | 2002-10-10 |
| KR20030083016A (en) | 2003-10-23 |
| EP1381598A4 (en) | 2008-03-19 |
| WO2002079192A1 (en) | 2002-10-10 |
| HRP20030844A2 (en) | 2005-08-31 |
| BG108206A (en) | 2004-11-30 |
| SK12002003A3 (en) | 2004-10-05 |
| GEP20053660B (en) | 2005-11-10 |
| JP2004534010A (en) | 2004-11-11 |
| ZA200307466B (en) | 2005-01-13 |
| UY27234A1 (en) | 2002-10-31 |
| HUP0400323A2 (en) | 2005-11-28 |
| CZ20032615A3 (en) | 2004-03-17 |
| NO20034308L (en) | 2003-11-26 |
| RU2003131693A (en) | 2005-05-10 |
| YU84603A (en) | 2006-03-03 |
| NO20034308D0 (en) | 2003-09-26 |
| AR035804A1 (en) | 2004-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300475A (en) | Tyrosine kinase inhibitors, pharmaceutical compositions containing them, and said compounds for use in the treatment of diseases | |
| CY2022009I1 (en) | DIHYDRONAPHTHYRIDINES AND RELATED COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF MULTIPLIARY DISEASES | |
| EE200300054A (en) | Bicyclopyrazoles acting as kinase inhibitors, process for their preparation, use and pharmaceutical compositions containing them | |
| DE60232251D1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ASTHMA | |
| EE200400015A (en) | Substituted Azaindoles, Pharmaceutical Composition Containing Them, and Use of Compounds and Composition for Inhibiting Protein Kinases | |
| EE200100717A (en) | Indazole Compounds and Pharmaceutical Compositions for the Inhibition of Protein Kinases and Methods for their Use | |
| DE50206657D1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| NO20032726L (en) | Quinazoline derivatives, medicaments containing these compounds, their use and method of preparation thereof | |
| ATE282428T1 (en) | PHARMACEUTICAL DOSAGE FORM OF AMORPHIC NILFENAVIR MESYLATE | |
| IL173348A (en) | Thienopyridine compounds, pharmaceutical compositions comprising same and use thereof in the preparation of medicaments | |
| NO324227B1 (en) | Cyclopropyl-fused pyrrolidine-based compounds, pharmaceutical compositions and combinations containing them as well as the use thereof for the manufacture of medicaments for the treatment of diseases | |
| HUP0202708A3 (en) | Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0400908A3 (en) | Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them | |
| HUP0202682A3 (en) | Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use | |
| IL175568A (en) | Tyrosine kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases | |
| IL164784A0 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| DE60142473D1 (en) | INTRAKORPORAL MEDICAMENTS FOR THE PHOTODYNAMIC TREATMENT OF ILLNESSES | |
| HUP0303146A3 (en) | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them | |
| EE05001B1 (en) | Heterocyclic compounds, process for their preparation, pharmaceutical composition containing them and their use in therapy | |
| DE60201859D1 (en) | Pharmaceutical use of N-carbamoylazole derivatives | |
| IT1318649B1 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MUCOSITES AND STOMATITIS. | |
| EE200300327A (en) | Urea derivatives, processes for their preparation, use and pharmaceutical composition | |
| EE200300167A (en) | Amidoalkylpiperidine and Piperazine Derivatives, Pharmaceutical Composition Containing Them, and Use of Compounds for the Treatment of Nervous System Disorders | |
| NO20041214L (en) | Substituted benzimidazole compounds and their use in the treatment of cancer | |
| EE200300473A (en) | Cyano-substituted dihydropyrimidine compounds and their use in the treatment of diseases |